肝细胞癌肝切除术后复发预防和治疗中国专家共识(2020版)

2021-01-25 中国实用外科杂志.2021.41(1):20-30.

肝细胞癌(hepatocellular carcinoma, HCC)是最常见的恶性肿瘤之一,全球发病率约84万/年,位居各种恶性肿瘤发病率的第7位。我国为HCC高发地区,发病率占全世界的50%以上。

中文标题:

肝细胞癌肝切除术后复发预防和治疗中国专家共识(2020版)

发布机构:

发布日期:

2021-01-25

简要介绍:

肝细胞癌(hepatocellular carcinoma, HCC)是最常见的恶性肿瘤之一,全球发病率约84万/年,位居各种恶性肿瘤发病率的第7位。我国为HCC高发地区,发病率占全世界的50%以上。最新统计资料表明,HCC在我国的肿瘤相关性死亡中位居第二位,仅次于肺癌。肝切除术仍是目前HCC治疗最常用的潜在根治性治疗手段,但文献报道的术后5年复发率>70%。有效预防与及时合理治疗复发,对降低病死率,提高总体生存率具有重大意义。为进一步规范和提高对HCC复发的临床防治水平,由国家科技部传染病防治重大专项课题《病毒性肝炎相关HCC外科综合治疗的个体化和新策略研究》专家组发起,根据国内外本领域研究进展,在该课题资助下开展临床研究取得的循证医学证据,结合既往符合我国国情的临床实践,制定本专家共识。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=肝细胞癌肝切除术后复发预防和治疗中国专家共识_2020版_夏勇.pdf)] GetToolGuiderByIdResponse(projectId=1, id=088a51c0020a63d1, title=肝细胞癌肝切除术后复发预防和治疗中国专家共识(2020版), enTitle=, guiderFrom=中国实用外科杂志.2021.41(1):20-30., authorId=0, author=, summary=肝细胞癌(hepatocellular carcinoma, HCC)是最常见的恶性肿瘤之一,全球发病率约84万/年,位居各种恶性肿瘤发病率的第7位。我国为HCC高发地区,发病率占全世界的50%以上。, cover=https://img.medsci.cn/2021130/1611941030938_2020535.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Mon Jan 25 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>肝细胞癌(hepatocellular carcinoma, HCC)是最常见的恶性肿瘤之一,全球发病率约84万/年,位居各种恶性肿瘤发病率的第7位。我国为HCC高发地区,发病率占全世界的50%以上。最新统计资料表明,HCC在我国的肿瘤相关性死亡中位居第二位,仅次于肺癌。肝切除术仍是目前HCC治疗最常用的潜在根治性治疗手段,但文献报道的术后5年复发率&gt;70%。有效预防与及时合理治疗复发,对降低病死率,提高总体生存率具有重大意义。为进一步规范和提高对HCC复发的临床防治水平,由国家科技部传染病防治重大专项课题《病毒性肝炎相关HCC外科综合治疗的个体化和新策略研究》专家组发起,根据国内外本领域研究进展,在该课题资助下开展临床研究取得的循证医学证据,结合既往符合我国国情的临床实践,制定本专家共识。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=357, tagName=肝细胞癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=91, categoryName=肝胆胰外科, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=357, guiderKeyword=肝细胞癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5666, appHits=344, showAppHits=0, pcHits=585, showPcHits=5322, likes=3, shares=181, comments=13, approvalStatus=1, publishedTime=Sat Jan 30 01:46:59 CST 2021, publishedTimeString=2021-01-25, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sat Jan 30 01:23:59 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 21:52:13 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=肝细胞癌肝切除术后复发预防和治疗中国专家共识_2020版_夏勇.pdf)])
肝细胞癌肝切除术后复发预防和治疗中国专家共识_2020版_夏勇.pdf
下载请点击:
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1202044, encodeId=5fac1202044aa, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c40a5730712, createdName=ms1000001218769596, createdTime=Sat Mar 12 19:25:25 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068417, encodeId=743f106841e1e, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9dc5566969, createdName=随行陆, createdTime=Tue Nov 09 09:28:26 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955633, encodeId=809d955633b4, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKEcicZP30abwxicCpWfZbx2L1Crv25v2p6klTsU2k28icODXXV9psyGEwZYhmCYCwibegDHe28Yxq06g/132, createdBy=95c55212198, createdName=147611aem14暂无昵称, createdTime=Sat Apr 10 08:41:09 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947212, encodeId=353d94e2121a, content=nb, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210310/0a95c3a8d47f41a48faefbc435dd2d38/13f3d200cc7c4a9e9df777811504eb7b.jpg, createdBy=22ca5466654, createdName=ms3000000868587726, createdTime=Wed Mar 10 19:49:22 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921471, encodeId=41fb9214e1bb, content=雪中送炭,👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210130/f777d0b91a25425ba588babbf050d6d1/328b4c90fd7741d090ece3b8f155fc70.jpg, createdBy=25525455713, createdName=牛洪凯, createdTime=Sat Jan 30 21:49:42 CST 2021, time=2021-01-30, status=1, ipAttribution=)]
    2022-03-12 ms1000001218769596

    积分

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1202044, encodeId=5fac1202044aa, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c40a5730712, createdName=ms1000001218769596, createdTime=Sat Mar 12 19:25:25 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068417, encodeId=743f106841e1e, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9dc5566969, createdName=随行陆, createdTime=Tue Nov 09 09:28:26 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955633, encodeId=809d955633b4, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKEcicZP30abwxicCpWfZbx2L1Crv25v2p6klTsU2k28icODXXV9psyGEwZYhmCYCwibegDHe28Yxq06g/132, createdBy=95c55212198, createdName=147611aem14暂无昵称, createdTime=Sat Apr 10 08:41:09 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947212, encodeId=353d94e2121a, content=nb, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210310/0a95c3a8d47f41a48faefbc435dd2d38/13f3d200cc7c4a9e9df777811504eb7b.jpg, createdBy=22ca5466654, createdName=ms3000000868587726, createdTime=Wed Mar 10 19:49:22 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921471, encodeId=41fb9214e1bb, content=雪中送炭,👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210130/f777d0b91a25425ba588babbf050d6d1/328b4c90fd7741d090ece3b8f155fc70.jpg, createdBy=25525455713, createdName=牛洪凯, createdTime=Sat Jan 30 21:49:42 CST 2021, time=2021-01-30, status=1, ipAttribution=)]
    2021-11-09 随行陆

    想看

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1202044, encodeId=5fac1202044aa, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c40a5730712, createdName=ms1000001218769596, createdTime=Sat Mar 12 19:25:25 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068417, encodeId=743f106841e1e, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9dc5566969, createdName=随行陆, createdTime=Tue Nov 09 09:28:26 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955633, encodeId=809d955633b4, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKEcicZP30abwxicCpWfZbx2L1Crv25v2p6klTsU2k28icODXXV9psyGEwZYhmCYCwibegDHe28Yxq06g/132, createdBy=95c55212198, createdName=147611aem14暂无昵称, createdTime=Sat Apr 10 08:41:09 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947212, encodeId=353d94e2121a, content=nb, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210310/0a95c3a8d47f41a48faefbc435dd2d38/13f3d200cc7c4a9e9df777811504eb7b.jpg, createdBy=22ca5466654, createdName=ms3000000868587726, createdTime=Wed Mar 10 19:49:22 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921471, encodeId=41fb9214e1bb, content=雪中送炭,👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210130/f777d0b91a25425ba588babbf050d6d1/328b4c90fd7741d090ece3b8f155fc70.jpg, createdBy=25525455713, createdName=牛洪凯, createdTime=Sat Jan 30 21:49:42 CST 2021, time=2021-01-30, status=1, ipAttribution=)]
    2021-04-10 147611aem14暂无昵称

    不错

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1202044, encodeId=5fac1202044aa, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c40a5730712, createdName=ms1000001218769596, createdTime=Sat Mar 12 19:25:25 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068417, encodeId=743f106841e1e, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9dc5566969, createdName=随行陆, createdTime=Tue Nov 09 09:28:26 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955633, encodeId=809d955633b4, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKEcicZP30abwxicCpWfZbx2L1Crv25v2p6klTsU2k28icODXXV9psyGEwZYhmCYCwibegDHe28Yxq06g/132, createdBy=95c55212198, createdName=147611aem14暂无昵称, createdTime=Sat Apr 10 08:41:09 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947212, encodeId=353d94e2121a, content=nb, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210310/0a95c3a8d47f41a48faefbc435dd2d38/13f3d200cc7c4a9e9df777811504eb7b.jpg, createdBy=22ca5466654, createdName=ms3000000868587726, createdTime=Wed Mar 10 19:49:22 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921471, encodeId=41fb9214e1bb, content=雪中送炭,👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210130/f777d0b91a25425ba588babbf050d6d1/328b4c90fd7741d090ece3b8f155fc70.jpg, createdBy=25525455713, createdName=牛洪凯, createdTime=Sat Jan 30 21:49:42 CST 2021, time=2021-01-30, status=1, ipAttribution=)]
    2021-03-10 ms3000000868587726

    nb

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1202044, encodeId=5fac1202044aa, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c40a5730712, createdName=ms1000001218769596, createdTime=Sat Mar 12 19:25:25 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068417, encodeId=743f106841e1e, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9dc5566969, createdName=随行陆, createdTime=Tue Nov 09 09:28:26 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955633, encodeId=809d955633b4, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKEcicZP30abwxicCpWfZbx2L1Crv25v2p6klTsU2k28icODXXV9psyGEwZYhmCYCwibegDHe28Yxq06g/132, createdBy=95c55212198, createdName=147611aem14暂无昵称, createdTime=Sat Apr 10 08:41:09 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947212, encodeId=353d94e2121a, content=nb, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210310/0a95c3a8d47f41a48faefbc435dd2d38/13f3d200cc7c4a9e9df777811504eb7b.jpg, createdBy=22ca5466654, createdName=ms3000000868587726, createdTime=Wed Mar 10 19:49:22 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921471, encodeId=41fb9214e1bb, content=雪中送炭,👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210130/f777d0b91a25425ba588babbf050d6d1/328b4c90fd7741d090ece3b8f155fc70.jpg, createdBy=25525455713, createdName=牛洪凯, createdTime=Sat Jan 30 21:49:42 CST 2021, time=2021-01-30, status=1, ipAttribution=)]
    2021-01-30 牛洪凯

    雪中送炭,👍

    0

拓展阅读

2013 JSH循证临床实践指南:肝细胞癌-更新版(JSH-HCC指南第3版)

日本肝脏学会(JSH,The Japan Society of Hepatology) · 2015-01-20

肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2016年版)

全国肝癌合并癌栓诊治研究协作组 · 2016-06-02

肝脏影像报告和数据系统管理工作组肝细胞癌诊断共识意见

美国肝病研究学会(AASLD,American Association for the Study of Liver Diseases) · 2016-06-02

肝细胞癌合并血管侵犯专家共识(讨论稿)

中国医疗保健国际交流促进会 · 2016-06-02

2014年KLCSG-NCC实践指南:肝细胞癌

暂未更新 · 2016-06-03